![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 10, 2023 10:10:41 AM
Pivot Point 2nd Level Resistance 0.8933
1-Month High 0.8550
Pivot Point 1st Resistance Point 0.8467
High 0.8100
Previous Close 0.8000
Last 0.7899
Low 0.7810
Pivot Point 1st Support Point 0.7617
Pivot Point 2nd Support Point 0.7233
Pivot Point 3rd Support Point 0.6767
Recent NRBO News
- NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 06/26/2024 01:06:00 PM
- NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/25/2024 09:08:00 PM
- NeuroBo Pharmaceuticals Announces up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • PR Newswire (US) • 06/24/2024 12:01:00 PM
- NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models • PR Newswire (US) • 06/22/2024 12:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 11:26:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 08:06:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 12:30:16 PM
- NeuroBo Pharmaceuticals' DA-1241 in Combination with Semaglutide Improves Liver Fibrosis and Demonstrates Additive Hepatoprotective Effects in Pre-Clinical MASH Models Compared to Either Treatment, Alone • PR Newswire (US) • 05/22/2024 12:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 01:00:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:05:51 PM
- NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/09/2024 12:01:00 PM
- NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June • PR Newswire (US) • 04/30/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 04/17/2024 12:05:00 PM
- NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 04/01/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/28/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH • PR Newswire (US) • 03/13/2024 12:01:00 PM
- NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer • PR Newswire (US) • 03/04/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 01:30:14 PM
- NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/29/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:52:22 PM
- NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference • PR Newswire (US) • 02/12/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:15 PM
- NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity • PR Newswire (US) • 02/01/2024 01:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 01:30:23 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM